Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report

References

• Zhang Q, He P, Tian T, et al. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: a prospective real-world study. Article. Front Pharmacol. 2023:141100556. doi:10.3389/fphar.2023.1100556
   Web of Science ®Google Scholar
• Sun H, Xu J, Dai S, Ma Y, Sun T. Breast cancer brain metastasis: current evidence and future directions. Review. Cancer Med. 2023;12(2):1007–1024. doi:10.1002/cam4.5021
   PubMed Web of Science ®Google Scholar
• Bertolini F, Spallanzani A, Fontana A, Depenni R, Luppi G. Brain metastases: an overview; Review. CNS Oncology. 2015;4(1):37–46. doi:10.2217/cns.14.51
   PubMedGoogle Scholar
• Wynn CS, Tang S-C. Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. Review. Cancer Metastasis Rev. 2022;41(1):193–209. doi:10.1007/s10555-022-10021-x
   PubMed Web of Science ®Google Scholar
• Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Article. Ann Oncol. 2020;31(10):1350–1358. doi:10.1016/j.annonc.2020.06.020
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu K, Wang M, Wang K, Zhu H. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: a cost-effectiveness analysis. Article. Breast. 2022;66:191–198. doi:10.1016/j.breast.2022.10.010
   PubMed Web of Science ®Google Scholar
• Witzel I, Oliveira-Ferrer L, Pantel K, Mueller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Review. Breast Cancer Res. 2016;188. doi:10.1186/s13058-015-0665-1
   Web of Science ®Google Scholar
• Perez-Garcia JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Article. Neuro-Oncology. 2023;25(1):157–166. doi:10.1093/neuonc/noac144
   PubMed Web of Science ®Google Scholar
• Custodio-Santos T, Videira M, Brito MA. Brain metastasization of breast cancer. Review. Biochim Et Biophys Acta Rev Cancer. 2017;1868(1):132–147. doi:10.1016/j.bbcan.2017.03.004
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu H, Han Y, Wu Y, Wang J. Comparative efficacy of tyrosine kinase inhibitors and antibody-drug conjugates in HER2-positive metastatic breast cancer patients with brain metastases: a systematic review and network meta-analysis. Review. Cancers. 2022;14(14):3372. doi:10.3390/cancers14143372
   PubMed Web of Science ®Google Scholar
• Lin NU, Diéras V, Paul D, et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–1459. doi:10.1158/1078-0432.Ccr-08-1080
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/S1470-2045(12)70432-1
   PubMed Web of Science ®Google Scholar
• Saleem A, Searle GE, Kenny LM, et al. Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015). EJNMMI Res. 2017:774. doi:10.1186/s13550-017-0323-y
   Google Scholar
• Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB Trial. Article. J Clin Oncol. 2020;38(23):2610–2619. doi:10.1200/jco.20.00775
   PubMed Web of Science ®Google Scholar
• Khatri VM, Mills MN, Oliver DE, et al. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases. Article; Early Access. J Neuro Oncol. 2023. doi:10.1007/s11060-023-04402-7
   PubMedGoogle Scholar
• Yan M, Ouyang QC, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022;23(3):353–361. doi:10.1016/S1470-2045(21)00716-6
   PubMed Web of Science ®Google Scholar
• Tian W, Hao S, Wang L, Chen Y, Li Z, Luo D. Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients. Article. Anti-Cancer Drugs. 2022;33(1):E622–E627. doi:10.1097/cad.0000000000001199
   PubMed Web of Science ®Google Scholar
• Ma X, Li Y, Li L, et al. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases. Article. Annals of Medicine. 2022;54(1):3085–3095. doi:10.1080/07853890.2022.2139411
   PubMed Web of Science ®Google Scholar
• Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a Phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081–1089. doi:10.1200/Jco.18.01511
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Saura C, Oliveira M, et al. Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist. 2021;26(8):E1327–E1338. doi:10.1002/onco.13830
   PubMed Web of Science ®Google Scholar
• Nasrazadani A, Brufsky A. Neratinib: the emergence of a new player in the management of HER2+breast cancer brain metastasis. Article. Future Oncol. 2020;16(7):247–254. doi:10.2217/fon-2019-0719
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Park YH, Yamashita T, et al. CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses. Meeting Abstract. Ann Oncol. 2020:31:S63–S64. doi:10.1016/j.annonc.2020.03.239
   Google Scholar
• Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Article. Nature Med. 2022;28(9):1840–1847. doi:10.1038/s41591-022-01935-8
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen X, Zhang H, et al. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Review. Cancer Commun. 2019:3936. doi:10.1186/s40880-019-0383-7
   Web of Science ®Google Scholar
• Zhong CC, Chen F, Yang JL, et al. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacol Sin. 2018;39(6):1048–1063. doi:10.1038/aps.2017.199
   PubMed Web of Science ®Google Scholar
• He Z, Liu J, Ma Y, et al. Anlotinib combined with cranial radiotherapy for non-small cell lung cancer patients with brain metastasis: a retrospectively, control study. Article. Cancer Manage Res. 2021;13:6101–6111. doi:10.2147/cmar.S319650
   PubMed Web of Science ®Google Scholar
• Xu Q, Huang K, Meng X, et al. Safety and efficacy of anlotinib hydrochloride plus temozolomide in patients with recurrent glioblastoma. Clin Cancer Res. 2023;29(19):3859–3866. doi:10.1158/1078-0432.Ccr-23-0388
   PubMed Web of Science ®Google Scholar
• Liu S, Zhi W, Zhang L. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: a retrospective observational study. Article; Early Access. J Cell Mol Med. 2023. doi:10.1111/jcmm.18008
   Web of Science ®Google Scholar
• Shao Y, Luo Z, Yu Y, et al. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer. Article. Front Oncol. 2022:12939343. doi:10.3389/fonc.2022.939343
   Google Scholar